Abroad Global Infrastructure Income Fund Q3 2025 Performance Review
ByAinvest
Thursday, Nov 13, 2025 1:17 pm ET1min read
TLX--
A securities fraud class action lawsuit has been filed against Telix Pharmaceuticals Limited (NASDAQ: TLX) alleging that the company made false and/or misleading statements about its progress with prostate cancer therapeutic candidates and supply chain quality. Investors who purchased Telix securities between February 21, 2025, and August 28, 2025, may be eligible to participate in the lawsuit. The lead plaintiff motion deadline is January 9, 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet